Nature Communications (Dec 2024)

SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers

  • Mahnaz Hosseinpour,
  • Xinqi Xi,
  • Ling Liu,
  • Luis Malaver-Ortega,
  • Laura Perlaza-Jimenez,
  • Jihoon E. Joo,
  • Harrison M. York,
  • Jonathan Beesley,
  • C. Elizabeth Caldon,
  • Pierre-Antoine Dugué,
  • James G. Dowty,
  • Senthil Arumugam,
  • Melissa C. Southey,
  • Joseph Rosenbluh

DOI
https://doi.org/10.1038/s41467-024-54824-8
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 12

Abstract

Read online

Abstract DNA methylation is an epigenetic mark that plays a critical role in regulating gene expression. DNA methyltransferase (DNMT) inhibitors, inhibit global DNA methylation and have been a key tool in studies of DNA methylation. A major bottleneck is the lack of tools to induce global DNA methylation. Here, we engineered a CRISPR based approach, that we initially designed, to enable site-specific DNA methylation. Using the synergistic activation mediator (SAM) system, we unexpectedly find that regardless of the targeted sequence any sgRNA induces global genome-wide DNA methylation. We term this method SAM-DNMT3A and show that induction of global DNA methylation is a unique vulnerability in ER-positive breast cancer suggesting a therapeutic approach. Our findings highlight the need of caution when using CRISPR based approaches for inducing DNA methylation and demonstrate a method for global induction of DNA methylation.